An interventional study of Inositol and alpha-lactalbumin in Metabolic Syndrome and Cardiac Fibrosis, sponsored by Lo.Li.Pharma s.r.l. Suspended at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Lo.Li.Pharma s.r.l · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Metabolic Syndrome with a site in Italy — 16 open to participants now, 18 under way, none of them phase 3. Metabolic Syndrome · Italy.
Among the 95 studies in Metabolic Syndrome with a site in Italy, this one is the 54th largest by planned enrollment of the 62 interventional ones that give a count, is one of 10 that started in 2022, is one of 38 with no phase, and was the 70th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →16 of the 95 studies in Metabolic Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Catholic University of the Sacred Heart · Sites in Italy
Ages 18+
Dr. Schär AG / SPA · Sites in Italy
Ages 18–60
Catholic University of the Sacred Heart · Sites in Italy
Ages 18–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 13–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 7 · Phase 4 9
First in 1996; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 71 across the 62 interventional studies, 200 across the 33 observational. Of the 59 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 95 have an industry lead sponsor. The 10 most frequent:
Lo.Li.Pharma s.r.l is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Lo.Li.Pharma s.r.l has 2 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06801769Catholic University of the Sacred HeartStudy for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells. | 2026-12 |
| NCT07155473Fondazione Policlinico Universitario Agostino Gemelli IRCCSIdentification of a Score for the Assessment of Intrapancreatic Fat | 2026-12 |
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT06647108ESIFood Supplement for Individuals with Metabolic Syndrome | 2027-01 |
| NCT07505277Dr. Schär AG / SPAStudy of the Effects of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Metabolic Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis
At least 3 of the following inclusion criteria:
Dietary Supplement with inositols and alpha-lactalbumin
Dietary Supplement: Inositol and alpha-lactalbumin
Drug pages: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LactalbuminStudies of LactalbuminLactalbumin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
Body weight
Time frame: Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days
Tryglicerides
Plasmatic levels of tryglicerides
Time frame: Four time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days
Hypertension
sphygmomanometer
Time frame: Four time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days
Started Dec 2022 (actual). Primary completion is estimated for Jan 2026, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Inositol · Lactalbumin